What Sufen Treats: Main Uses and Benefits

Sufen is commonly used across therapeutic domains involving symptoms related to inflammatory or irritative states and physical discomfort. The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns, primarily to ease symptoms related to physical discomfort. It is applied in cases where supportive symptom management is appropriate.

Therapeutic Scope and Benefits

Sufen is relevant for managing symptoms in conditions like chronic joint diseases, specifically Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, as well as in acute scenarios such as soft-tissue injuries (sprains and strains) and the acute physical discomfort of dysmenorrhea. It helps address symptom clusters that may become intense or disruptive, such as persistent pain and swelling. The supportive relief offered by Sufen assists with maintaining functional stability when symptoms are more noticeable, particularly for symptoms that interfere with daily functioning, like pronounced joint stiffness.

“The support provided is centered on easing the discomfort and symptoms related to inflammatory or irritative states, thereby supporting the patient during difficult episodes.”

Quick Fact: Support for Discomfort and Strain
Symptom Axes	Patient Benefit Framing
Symptoms related to physical discomfort	Helps ease the overall symptom load
Symptoms that interfere with daily functioning	Assists with maintaining functional stability
Symptoms related to inflammatory or irritative states	Contributes to improved comfort during periods of heightened symptoms

Regulatory References

1. Health Canada Product Monograph on Tiaprofenic Acid

Eligibility Map: Who Can and Cannot Use Sufen — Official Regulatory Information

The official eligibility criteria for Sufen (Tiaprofenic Acid) are determined by age, medical history, and physiological status, as stated in regulatory documents.

Category	Official Regulatory Status
Populations for whom use is allowed	Adults (18 years of age or older). Use is established for labeled indications.
Populations for whom use is not recommended	Pediatric population (under 18 years old); Women planning pregnancy; Patients with non-severe kidney or liver impairment.

---

Populations for Whom Use is Contraindicated

Sufen is absolutely contraindicated (must not be used) in patients with:

• A known allergy to Tiaprofenic Acid, aspirin, or any other NSAIDs.
• Active peptic ulceration or a history of recurrent gastrointestinal bleeding.
• Severe renal or hepatic impairment; uncontrolled heart failure; or active bleeding disorders.
• The third trimester of pregnancy (at or after 30 weeks gestation) and during breastfeeding.
• The peri-operative period of Coronary Artery Bypass Graft (CABG) surgery.

---

Age- and Condition-Specific Rules

• Pediatric Use: Use is not established and not recommended in children and adolescents under 18 years of age.
• Older Adults: Use requires caution due to a greater risk for serious gastrointestinal and cardiovascular events.
• Pregnancy: Use is contraindicated in the third trimester. Use between 20 and 30 weeks is conditional, requiring the lowest effective dose for the shortest duration.

---

Connection to the overall eligibility profile: Regulatory labeling strictly defines who can and cannot use the medicine by limiting eligible patients to adults and imposing absolute prohibitions based on critical health statuses such as severe organ failure, specific surgical risk, and reproductive condition.

Sufen (Tiaprofenic Acid) has a regulatory-defined interaction profile that strictly prohibits certain combinations and requires specific administration rules.

Contraindicated Combinations

Co-administration is formally contraindicated with other nonsteroidal anti-inflammatory drugs (NSAIDs), salicylate drugs such as Aspirin, and Pemetrexed. The medication must also not be used immediately before or after coronary artery bypass graft (CABG) surgery.

Pharmacodynamic and Exposure Risks

When combined with Anticoagulants or Anti-platelet drugs, there is a documented risk of increased bleeding and hemorrhage. Co-administration with ACE inhibitors, ARBs, and Diuretics may diminish the therapeutic effect of these agents and increase the risk of renal failure and hyperkalemia. Sufen also increases the risk of toxicity for agents such as Lithium and Methotrexate by reducing their excretion.

Administration and Substance Restrictions

Regulatory documents specify that Sufen must be taken with or after food to mitigate potential gastrointestinal irritation. Additionally, daily use of alcohol and tobacco may increase the risk for stomach bleeding. Regulatory labeling notes that elderly patients and those with impaired renal function are at a greater risk of adverse outcomes when Sufen is combined with interacting medicines.

Mechanism of Action: Tiaprofenic Acid

Sufen's mechanism is defined by the non-covalent inhibition of the Cyclooxygenase (COX) enzyme system, affecting both COX-1 and COX-2 isoforms. This targeted molecular interference prevents the COX-mediated conversion of Arachidonic Acid into prostaglandins, which are key chemical mediators. By blocking this initial molecular step, the drug modifies the downstream inflammatory and nociceptive signaling cascade.

The resultant decrease in prostaglandin biosynthesis is central to the modulation of the Peripheral Nociceptive Pathway. Prostaglandins typically lower the activation threshold of pain-sensing nerve endings (nociceptors); their reduction raises this physiological threshold, functionally restricting the transmission of nociceptive signals. This change also affects local vascular dynamics, limiting the prostaglandin-driven capillary permeability and subsequent fluid accumulation in the affected tissue.

Secondary to COX inhibition, the drug possesses a mechanism involving the stabilization of lysosomal membranes, affecting the resistance of cellular components to inflammatory breakdown. The overall modulation is functionally constrained, being primarily relevant in contexts where prostaglandin mediators dominate the physiological response, and does not extend to processes mediated by non-COX pathways.

How Sufen Is Used: Administration Guidelines

Sufen (Tiaprofenic Acid) is administered by the oral route, primarily available in conventional and sustained-release tablet dosage forms. The general principle of use follows established protocols that define the conditions for intake, the dose range, and frequency.

Standard Dosing and Frequency

The standard adult daily dosage is typically 600 mg, though the range may be initiated between 300 mg and 600 mg per day. The total daily dose must not exceed 600 mg. This total amount is generally administered in two or three divided doses throughout the day, ensuring a consistent level of the compound. For instance, this may involve taking a 300 mg tablet twice daily or 200 mg three times daily.

Contextual Administration Rules

Correct administration involves specific contextual rules. Sufen is taken with or immediately after a meal to satisfy the requirements for optimal intake. The tablets must be swallowed whole with a sufficient amount of water. Sustained-release tablets must not be crushed, chewed, or split, as this action would compromise the intended release profile of the formulation.

Population-Specific Dosing

Guidelines require the use of the lowest effective dose for the shortest necessary duration, a principle particularly emphasized for older adults. For this population, a reduced initial dose is generally advised. Additionally, patients with renal impairment require special consideration, often involving a dose reduction, to account for altered compound excretion.

Research Evidence / Overview of Studies for Sufen

Evidence for use in Perioperative Pain Management

Research has been studied primarily through short-term randomized controlled trials (RCTs) conducted in hospital settings. These studies focused on patients experiencing outcomes related to physical discomfort during or immediately after surgery. Researchers monitored outcomes describing episodic or acute changes in symptom intensity, as well as the time it took for patients to report initial change and how long the measured outcome related to physical discomfort was observed.

Findings described patterns observed in the studies where patient-reported outcomes evolved in the observed populations during the defined time intervals. These studies also monitored physiological strain or stress, such as respiratory rate, to evaluate systemic effects in research contexts involving fluctuating or unstable symptoms. The evidence so far describes patterns that were specific to the short-term periods immediately following administration.

Comparing Sufen to Placebo and Other Treatments

Some research involved studies conducted during periods of increased symptom activity that directly compared the agent to a placebo or to other common pain medications. These trials used standardized patient-reported outcomes to assess the comparative changes measured during the study period.

Findings described patterns related to how symptom intensity or variability was observed when Sufen was evaluated in these comparator settings. Some studies reported measurements that differed from those in the placebo group; however, the comparative evidence against other standard therapies was associated with mixed findings. The research highlights changes measured, but it does not determine whether an individual will respond similarly or have a better outcome compared to other available options.

Long-Term Studies and Follow-Up Data

Studies focusing on outcomes that extend beyond the brief periods immediately following surgery are limited. Most primary evidence covers the period of acute physical discomfort. Research has explored short-term symptom changes, but long-term effects are not fully established.

What Research is Still Uncertain About Sufen

There are several areas where the research landscape remains uncertain. Because most studies explored short-term symptom changes, the long-term effects are not fully established, and follow-up durations were limited. Data are still emerging for certain highly specific subgroups, and the evidence quality varies across studies based on their design and size.

Common questions about Sufen (FAQ)

---

Q: Does Sufen interact with alcohol?

Regulatory labeling addresses the concurrent use of Sufen and alcohol. Official patient information states that the daily use of alcohol, when combined with Sufen, may increase the potential for stomach bleeding.

---

Q: What are the documented clinical trial results for Sufen?

Clinical research, primarily consisting of short-term randomized controlled trials, has examined changes in reported pain and inflammation. Findings documented outcomes that were observed to be different from those in the placebo group. Comparative evidence against other standard treatments has been described as having mixed findings.

---

Q: Is the long-term effectiveness of Sufen supported by research?

Most of the primary research evidence for Sufen focuses on short-term symptom changes, such as those immediately following administration. Because follow-up periods in studies were limited, the long-term effects of Sufen are not yet fully established or characterized.

---

Q: Can Sufen be safely used by individuals with kidney or liver issues?

Official documents describe Sufen as contraindicated (must not be used) in patients with severe renal (kidney) or hepatic (liver) impairment. Use in patients with less severe impairment requires caution and may involve a prescribed dose reduction.

---

Q: What should I do if I suspect an interaction between Sufen and another medication?

Official patient information advises consulting a doctor or pharmacist for guidance if you are concerned about potential interactions between Sufen and other medications, including any medicines you are already taking. Consulting a professional allows for a proper evaluation of the potential risk.

---

Q: What does official guidance say about stopping Sufen?

Official patient medication information generally advises individuals not to stop taking this medication without first consulting their prescribing healthcare professional. This guidance aligns with the principle of professional oversight for changes in prescribed medical treatment.

---

Q: Is Sufen available over the counter, or do I need a prescription?

Sufen is classified as a prescription medicine. The dose, frequency, and conditions for use are determined by a qualified healthcare professional who has assessed the patient's condition.

---

Q: How long does it typically take for Sufen to start working?

Studies and official information indicate that it may take some time to notice the full benefits of the medication. To achieve the full benefit for its intended use, official information indicates it may take up to two weeks of regular use as described by a healthcare professional.

---

Q: Does Sufen cause drowsiness or affect my ability to drive?

Official information lists drowsiness and dizziness as reported side effects. Official patient information notes that activities like driving or operating machinery should be avoided until a person is aware of how the medication affects them.

---

Q: Is it possible to take Sufen only when I feel I need it?

The general principle for using Sufen involves taking the total daily dose in two or three divided doses throughout the day. This schedule is designed to ensure a consistent level of the compound in the body, which is essential for its therapeutic effect.

---

Q: Are there any long-term health risks associated with taking Sufen?

Official documents note that, as with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), there is an increased risk of serious events such as cardiovascular issues and gastrointestinal bleeding. This risk is particularly noted with long-term use or in people who have pre-existing conditions.

---

Q: Can Sufen affect my mood or mental clarity?

Regulatory information lists potential adverse effects involving the central nervous system. These may include dizziness, confusion, and reported mental or mood changes.

---

Q: What happens if I miss a scheduled dose of Sufen?

Official guidance states that if a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped entirely. Official guidance emphasizes that a double dose should not be taken to compensate for a missed dose.

---

Q: What should I know about taking Sufen during pregnancy or while breastfeeding?

Sufen is absolutely contraindicated (must not be used) during the third trimester of pregnancy (at or after 30 weeks gestation) and while breastfeeding. The regulatory status for use between 20 and 30 weeks is conditional and generally requires the lowest effective dose for the shortest duration.

---

Q: Do food or certain types of drinks affect how Sufen works?

Administration instructions require Sufen to be taken with or immediately after a meal. This condition is specified to fulfill the labeled administration requirements and help mitigate potential gastrointestinal irritation.

---

Q: How is Sufen meant to fit into a long-term treatment plan?

Official guidance for Sufen, as with other NSAIDs, emphasizes using the lowest effective dose for the shortest necessary duration to minimize the risk of adverse effects. The individual length of treatment is determined by the prescribing health professional.

---

Q: Can Sufen be crushed, cut, or chewed?

The instructions for use state that sustained-release tablets must not be crushed, chewed, or split because this would compromise the intended slow-release profile of the formulation. Conventional tablets are intended to be swallowed whole with a sufficient amount of water.

---

Q: Is it normal to feel a change in appetite while taking Sufen?

While regulatory information lists loss of appetite as a reported event, it is primarily noted as a symptom that may accompany signs of potential liver damage. It is not generally classified in official documents as a stand-alone common side effect.

---

Q: Is Sufen addictive or habit-forming?

Sufen is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its official regulatory information does not classify it as an opioid or schedule I-V controlled substance, which are the categories for drugs considered to be addictive or habit-forming.

---

Q: Are there any specific lifestyle changes recommended when starting Sufen?

Regulatory documents note an increased risk of stomach bleeding with the daily use of alcohol and tobacco. Additionally, regulatory information notes that activities requiring full alertness, such as driving, should be approached with caution.

---

Q: How quickly is Sufen eliminated from the body?

The time it takes for the active ingredient, Tiaprofenic Acid, to be processed and eliminated from the body is documented. Its biological half-life is short, typically ranging between 1.5 to 2.5 hours.

---

Q: Can Sufen interact with common pain relievers like ibuprofen or acetaminophen?

Sufen is formally contraindicated with other nonsteroidal anti-inflammatory drugs (NSAIDs) and salicylate drugs like Aspirin, meaning they should not be combined. The risk or severity of adverse effects can also be increased when Sufen is combined with Acetaminophen.

---

Q: Does Sufen require any special monitoring or lab tests?

The necessity for special monitoring, such as blood or liver function tests, is determined on a case-by-case basis by a healthcare professional. Monitoring may be advised, particularly for older adults or those taking the medication for a long period of time.

---

Q: What is the average duration of treatment with Sufen?

Official guidance is to use Sufen for the shortest necessary duration to achieve symptomatic relief. The length of treatment is not standardized and is defined by the prescribing health professional based on the specific condition being managed.

---

Q: Does Sufen have a potential for allergic reactions?

Sufen is contraindicated in patients with a known allergy or hypersensitivity to the drug or to other NSAIDs. Signs of a severe allergic reaction may include swelling of the face or throat and difficulty breathing.

---

Q: What are the main scientific conclusions from the major studies on Sufen?

Research supports the use of Sufen for symptomatic relief from pain and inflammation, with studies demonstrating measured changes in symptom intensity. However, the available comparative evidence against other standard therapies was associated with mixed findings.

---

Q: Can taking Sufen affect my blood pressure or heart rate?

Regulatory information reports adverse reactions involving the cardiovascular system, including hypotension (low blood pressure) and bradycardia (slow heart rate). Official documents also note that Sufen, like other NSAIDs, may cause blood pressure to increase.

---

Q: Has Sufen been approved in other major countries besides the US?

The active ingredient in Sufen, Tiaprofenic Acid, has an official Anatomical Therapeutic Chemical (ATC) code and is referenced in the regulatory documents of several major health authorities outside of the US, including Canada and the European Medicines Agency (EMA).

How to Store and Dispose of Sufen (Tiaprofenic Acid)

Storage Conditions

Sufen tablets must be stored at room temperature, typically below 25 C or 30 C, as defined by regulatory labeling. It is mandatory to protect the medicine from moisture and light and keep it in its original packaging to maintain stability up to the expiry date. All medicines must be kept out of the sight and reach of children and pets.

Disposal Requirements

Unused or expired Sufen must not be disposed of in household waste or wastewater (e.g., flushed down the toilet). To ensure proper disposal, consult a pharmacist or local authorized drug collection program for instructions on safely discarding the medicine.